| Bioactivity | JYQ-194 is a proteolysis targeting chimera (PROTAC) designed to target human Parkinson's disease protein 7 (PARK7). It operates by binding to the E3 ubiquitin ligase cereblon, facilitating the ubiquitination of PARK7, which in turn targets PARK7 for degradation via the proteasome. JYQ-194 holds potential for research in both cancer and neurodegenerative diseases[1]. |
| Formula | C39H38FN11O8S |
| Molar Mass | 839.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jia Y, et al. Development of Inhibitors, Probes, and PROTAC Provides a Complete Toolbox to Study PARK7 in the Living Cell[J]. Journal of Medicinal Chemistry, 2024. |